JP2019510001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510001A5 JP2019510001A5 JP2018544185A JP2018544185A JP2019510001A5 JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5 JP 2018544185 A JP2018544185 A JP 2018544185A JP 2018544185 A JP2018544185 A JP 2018544185A JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 77
- 239000005557 antagonist Substances 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 44
- 239000002955 immunomodulating agent Substances 0.000 claims description 20
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 18
- 230000001394 metastastic effect Effects 0.000 claims description 18
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 9
- 102000015696 Interleukins Human genes 0.000 claims description 8
- 108010063738 Interleukins Proteins 0.000 claims description 8
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 6
- 230000000683 nonmetastatic effect Effects 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 6
- 102100034134 Activin receptor type-1B Human genes 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- -1 ActRIIA Proteins 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 4
- 229940122004 CD47 antagonist Drugs 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 4
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 4
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims description 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 4
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 4
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 4
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims description 4
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims description 4
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 4
- 108010023082 activin A Proteins 0.000 claims description 4
- 108010023079 activin B Proteins 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 229960003347 obinutuzumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 108700042805 TRU-015 Proteins 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 229950009090 ocaratuzumab Drugs 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 229960005267 tositumomab Drugs 0.000 claims description 2
- 229950000815 veltuzumab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- 238000009472 formulation Methods 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 80
- 230000028993 immune response Effects 0.000 description 14
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 239000013543 active substance Substances 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 150000003384 small molecules Chemical group 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 102000013135 CD52 Antigen Human genes 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 229960003852 atezolizumab Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 230000005924 vaccine-induced immune response Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023843A JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298366P | 2016-02-22 | 2016-02-22 | |
| US62/298,366 | 2016-02-22 | ||
| PCT/US2017/018938 WO2017147182A1 (en) | 2016-02-22 | 2017-02-22 | Actrii antagonists for use in increasing immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Division JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510001A JP2019510001A (ja) | 2019-04-11 |
| JP2019510001A5 true JP2019510001A5 (enExample) | 2020-04-09 |
| JP7058606B2 JP7058606B2 (ja) | 2022-04-22 |
Family
ID=59629767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544185A Active JP7058606B2 (ja) | 2016-02-22 | 2017-02-22 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170240639A1 (enExample) |
| EP (1) | EP3420002A4 (enExample) |
| JP (2) | JP7058606B2 (enExample) |
| KR (1) | KR20180128405A (enExample) |
| CN (1) | CN109311998A (enExample) |
| AU (1) | AU2017222526A1 (enExample) |
| CA (1) | CA3014197A1 (enExample) |
| WO (1) | WO2017147182A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| EP3522913A4 (en) | 2016-10-05 | 2020-10-28 | Acceleron Pharma Inc. | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| AU2018214979A1 (en) * | 2017-02-01 | 2019-08-15 | Acceleron Pharma Inc. | TGFβ and actrii antagonists for use in increasing immune activity |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN108129572B (zh) * | 2018-01-04 | 2021-01-29 | 河南大学 | 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用 |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| EP4025248A1 (en) | 2019-09-03 | 2022-07-13 | Novartis AG | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| CN115135330A (zh) * | 2019-10-10 | 2022-09-30 | 纽约干细胞基金会有限公司 | 修饰的干细胞及其使用方法 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3228901A1 (en) * | 2021-09-03 | 2023-03-09 | Chris Xiangyang Lu | Anti-acvr2a antibodies and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677007A1 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| ES2796121T3 (es) * | 2009-08-13 | 2020-11-25 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| CA2773494A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| KR101438265B1 (ko) * | 2011-04-04 | 2014-09-05 | 한국생명공학연구원 | Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| US9453080B2 (en) * | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| AU2015274293A1 (en) * | 2014-06-13 | 2017-02-02 | Amgen Inc. | Formulated receptor polypeptides and related methods |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
-
2017
- 2017-02-22 CN CN201780024969.4A patent/CN109311998A/zh active Pending
- 2017-02-22 US US15/439,386 patent/US20170240639A1/en not_active Abandoned
- 2017-02-22 EP EP17757142.9A patent/EP3420002A4/en active Pending
- 2017-02-22 WO PCT/US2017/018938 patent/WO2017147182A1/en not_active Ceased
- 2017-02-22 JP JP2018544185A patent/JP7058606B2/ja active Active
- 2017-02-22 CA CA3014197A patent/CA3014197A1/en active Pending
- 2017-02-22 AU AU2017222526A patent/AU2017222526A1/en not_active Abandoned
- 2017-02-22 KR KR1020187027012A patent/KR20180128405A/ko not_active Abandoned
-
2022
- 2022-02-18 JP JP2022023843A patent/JP2022062277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510001A5 (enExample) | ||
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Elster et al. | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | |
| Jones et al. | Evolving novel anti-HER2 strategies | |
| Ganesan et al. | Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma | |
| Duffy et al. | Immunological off-target effects of standard treatments in gastrointestinal cancers | |
| Arora et al. | Immunotherapy in colorectal cancer: for the select few or all? | |
| Duarte et al. | Gastric cancer: Basic aspects | |
| Goel et al. | Cancer immunotherapy in clinical practice—the past, present, and future | |
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| Saavedra et al. | CIMAvax-EGF: Toward long-term survival of advanced NSCLC | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Zibelman et al. | Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck | |
| Kersh et al. | Targeted therapies: immunologic effects and potential applications outside of cancer | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| Chung et al. | Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis | |
| Lam et al. | Refractory metastatic colorectal cancer: current challenges and future prospects | |
| AU2020241963A1 (en) | Treatment of cancers using sEphB4-HSA fusion proteins | |
| JP2018509423A5 (enExample) | ||
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| Msaouel et al. | Immune checkpoint therapy in head and neck cancers | |
| Terrero et al. | Role of immunotherapy in advanced gastroesophageal cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Kim et al. | Current status and perspective of immunotherapy in gastrointestinal cancers |